17
Background:
In low- and middle-income countries, patients face high out-of-pocket expenses for consultations, diagnostics, chemotherapy, radiotherapy, and surgery contributing to treatment delays or discontinuation. COST-FIN is the first randomized controlled trial evaluating whether structured financial nav...
D. Ebekue, F. Wuraola, Titilope Ogunniyi et al.· JCO Oncology Practice· 0 citations
Within COST- FIN, RAs, data quality oversight, and in-country project management were essential to trial operations, financial data integrity, and cross-site implementation fidelity.
Z. Adegbite, Clement Awe, T. Aduloju et al.· JCO Global Oncology· 0 citations
Pediatric osteosarcoma remains a major cause of cancer-related morbidity and mortality among children and adolescents in sub-Saharan Africa, where late presentation, limited diagnostic resources, and restricted access to multimodal therapy significantly affect outcomes. There is a lack of region-specific data des...
Adedayo Joseph, A. Akinsete, A. Alabi et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
